nach oben

Erschienen in:

04.12.2017 | Systematic Review

Polymyxin B-immobilized hemoperfusion and mortality in critically ill adult patients with sepsis/septic shock: a systematic review with meta-analysis and trial sequential analysis

verfasst von: Tomoko Fujii, Riki Ganeko, Yuki Kataoka, Toshi A. Furukawa, Robin Featherstone, Kent Doi, Jean-Louis Vincent, Daniela Pasero, René Robert, Claudio Ronco, Sean M. Bagshaw

Erschienen in: Intensive Care Medicine | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Polymyxin B-immobilized hemoperfusion (PMX-HP) is an adjuvant therapy for sepsis or septic shock that clears circulating endotoxin. Prior trials have shown that PMX-HP improves surrogate endpoints. We aimed to conduct an evidence synthesis to evaluate the efficacy and safety of PMX-HP in critically ill adult patients with sepsis or septic shock.

Methods

We searched for randomized controlled trials (RCTs) in MEDLINE, EMBASE, the Cochrane Library, the Health Technology Assessment Database, CINAHL, “Igaku Chuo Zasshi”, the National Institute of Health Clinical Trials Register, the World Health Organization International Clinical Trials Registry Platform, the University Hospital Medical Information Network Clinical Trials Registry, the reference lists of retrieved articles, and publications by manufacturers of PMX-HP. The primary outcomes were 28-day all-cause mortality, the number of patients with at least one serious adverse event, and organ dysfunction scores. The GRADE methodology for the certainty of evidence was used.

Results

Six trials (857 participants; weighted mean age 62.5 years) proved eligible. Patient-oriented primary outcomes were assessed. The pooled risk ratio (RR) for 28-day mortality associated with PMX-HP was 1.03 [95% confidence interval (CI) 0.78–1.36; I ² = 25%; n = 797]. The pooled RR for adverse events was 2.17 (95% CI 0.68–6.94; I ² = 0%; n = 717). Organ dysfunction scores over 24–72 h after PMX-HP treatment did not change significantly (standardized mean difference − 0.26; 95% CI − 0.64 to 0.12; I ² = 78%; n = 797). The certainty of the body of evidence was judged as low for both benefit and harm using the GRADE methodology.

Conclusions

There is currently insufficient evidence to support the routine use of PMX-HP to treat patients with sepsis or septic shock.

Registration

PROSPERO International Prospective Register of Systematic Reviews (CRD42016038356).

Nur mit Berechtigung zugänglich

Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R (2014) Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000–2012. JAMA 311:1308–1316CrossRefPubMed

Rhee C, Dantes R, Epstein L et al (2017) CDC prevention epicenter program: benchmarking the incidence and mortality of severe sepsis in the United States. JAMA. https://doi.org/10.1001/jama.2017.13836 (Epub ahead of print) PubMedCentralCrossRefPubMed

Quenot JP, Binquet C, Kara F et al (2013) The epidemiology of septic shock in French intensive care units: the prospective multicenter cohort EPISS study. Crit Care 17:R65CrossRefPubMedPubMedCentral

Leligdowicz A, Dodek PM, Norena M, Co-operative Antimicrobial Therapy of Septic Shock Database Research Group et al (2014) Association between source of infection and hospital mortality in patients who have septic shock. Am J Respir Crit Care Med 189:1204–1213CrossRefPubMed

Singer M, Deutschman CS, Seymour CW et al (2016) The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 315:801–810CrossRefPubMedPubMedCentral

Suffredini AF, Munford RS (2011) Novel therapies for septic shock over the past 4 decades. JAMA 306:194–199CrossRefPubMed

Dellinger RP, Carlet JM, Masur H, Surviving Sepsis Campaign Management Guidelines Committee et al (2004) Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 32:858–873CrossRefPubMed

Dellinger RP, Levy MM, Rhodes A, Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup et al (2013) Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 41:580–637CrossRefPubMed

Danner RL, Elin RJ, Hosseini JM, Wesley RA, Reilly JM, Parillo JE (1991) Endotoxemia in human septic shock. Chest 99:169–175CrossRefPubMed

10.

Casey LC, Balk RA, Bone RC (1993) Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 119:771–778CrossRefPubMed

11.

Marshall JC, Foster D, Vincent JL, MEDIC study et al (2004) Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis 190:527–534CrossRefPubMed

12.

Shoji H, Tani T, Hanasawa K, Kodama M (1998) Extracorporeal endotoxin removal by polymyxin B immobilized fiber cartridge: designing and antiendotoxin efficacy in the clinical application. Ther Apher 2:3–12CrossRefPubMed

13.

Shoji H (2003) Extracorporeal endotoxin removal for the treatment of sepsis: endotoxin adsorption cartridge (Toraymyxin). Ther Apher Dial 7:108–114CrossRefPubMed

14.

Vincent JL, Laterre PF, Cohen J et al (2005) A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 23:400–405CrossRefPubMed

15.

Cruz DN, Antonelli M, Fumagalli R et al (2009) Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 301:2445–2452CrossRefPubMed

16.

Cruz DN, Perazella MA, Bellomo R et al (2007) Effectiveness of polymyxin B-immobilized fiber column in sepsis: a systematic review. Crit Care 11:R47CrossRefPubMedPubMedCentral

17.

Payen DM, Guilhot J, Launey Y, ABDOMIX Group et al (2015) Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med 41:975–984CrossRefPubMedPubMedCentral

18.

Dellinger P (2016) EUPHRATES: evaluating the use of polymyxin B hemoperfusion in a randomized controlled trial of adults treated for endotoxemia and septic shock. Canadian Critical Care Forum, Toronto

19.

Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097CrossRefPubMedPubMedCentral

20.

Fujii T, Ganeko R, Kataoka Y, Featherstone R, Bagshaw S, Furukawa TA (2016) Polymyxin B-immobilised haemoperfusion and mortality in critically ill patients with sepsis/septic shock: a protocol for a systematic review and meta-analysis. BMJ Open 6:e012908CrossRefPubMedPubMedCentral

21.

Levy MM, Fink MP, Marshall JC, International Sepsis Definitions Conference et al (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS international sepsis definitions conference. Intensive Care Med 29:530–538CrossRefPubMed

22.

Vincent JL, de Mendonça A, Cantraine F et al (1998) Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on “sepsis-related problems” of the European Society of Intensive Care Medicine. Crit Care Med 26:1793–1800CrossRefPubMed

23.

Sampson M, McGowana J, Cogob E, Grimshaw J, Moherd D, Lefebvre C (2009) An evidence-based practice guideline for the peer review of electronic search strategies. J Clin Epidemiol 62:944–952CrossRefPubMed

24.

Higgins JPT, Green S (2008) Cochrane handbook for Systematic Reviews of Interventions. John Wiley & Sons, Chichester (UK)CrossRef

25.

Vincent JL, Moreno R, Takala J et al (1996) The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the working group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22:707–710CrossRefPubMed

26.

Cook R, Cook D, Tilley J, Lee K, Marshall J, Canadian Critical Care Trials Group (2001) Multiple organ dysfunction: baseline and serial component scores. Crit Care Med 29:2046–2050CrossRefPubMed

27.

da Costa BR, Nüesch E, Rutjes AW et al (2013) Combining follow-up and change data is valid in meta-analyses of continuous outcomes: a meta-epidemiological study. J Clin Epidemiol 66:847–855CrossRefPubMed

28.

Review Manager (RevMan) [Computer program] (2014) Version 5.3. The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen

29.

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188CrossRefPubMed

30.

Guyatt G, Oxman AD, Akl EA et al (2011) GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64:383–394CrossRefPubMed

31.

Cantaluppi V, Assenzio B, Pasero D et al (2008) Polymyxin-B hemoperfusion inactivates circulating proapoptotic factors. Intensive Care Med 34:1638–1645CrossRefPubMedPubMedCentral

32.

Nakamura T, Ushiyama C, Suzuki Y et al (2003) Combination therapy with polymyxin B-immobilized fibre haemoperfusion and teicoplanin for sepsis due to methicillin-resistant Staphylococcus aureus. J Hosp Infect 53:58–63CrossRefPubMed

33.

Berto P, Ronco C, Cruz D, Melotti RM, Antonelli M (2011) Cost-effectiveness analysis of polymyxin-B immobilized fiber column and conventional medical therapy in the management of abdominal septic shock in Italy. Blood Purif 32:331–340CrossRefPubMed

34.

Klein DJ, Foster D, Schorr CA, Kazempour K, Walker PM, Dellinger RP (2014) The EUPHRATES trial (evaluating the use of polymyxin B hemoperfusion in a randomized controlled trial of adults treated for endotoxemia and septic shock): study protocol for a randomized controlled trial. Trials. 15:218CrossRefPubMedPubMedCentral

35.

Honore PM, Jamez J, Wauthier M et al (2000) Prospective evaluation of short-term, high-volume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med 28:3581–3587CrossRefPubMed

36.

Bellomo R, Kellum JA, Gandhi CR et al (2000) The effect of intensive plasma water exchange by hemofiltration on hemodynamics and soluble mediators in canine endotoxemia. Am J Respir Crit Care Med 161:1429–1436CrossRefPubMed

37.

Cornejo R, Downey P, Castro R et al (2006) High-volume hemofiltration as salvage therapy in severe hyperdynamic septic shock. Intensive Care Med 32:713–722CrossRefPubMed

38.

VA/NIH Acute Renal Failure Trial Network (2008) Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 359:7–20CrossRef

39.

RENAL Replacement Therapy Study Investigators (2009) Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med 361:1627–1638CrossRef

40.

Van Wert R, Friedrich JO, Scales DC et al (2010) High-dose renal replacement therapy for acute kidney injury: systematic review and meta-analysis. Crit Care Med 38:1360–1369CrossRefPubMed

41.

Payen D, Mateo J, Cavaillon JM et al (2009) Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: a randomized controlled trial. Crit Care Med 37:803–810CrossRefPubMed

42.

Zhou F, Peng Z, Murugan R, Kellum JA (2013) Blood purification and mortality in sepsis: a meta-analysis of randomized trials. Crit Care Med 41:2209–2220CrossRefPubMedPubMedCentral

43.

Chang T, Tu YK, Lee CT et al (2017) Effects of polymyxin b hemoperfusion on mortality in patients with severe sepsis and septic shock: a systemic review, meta-analysis update, and disease severity subgroup meta-analysis. Crit Care Med 45:e858–e864CrossRefPubMedPubMedCentral

44.

Nemoto H, Nakamoto H, Okada H et al (2001) Newly developed immobilized polymyxin B fibers improve the survival of patients with sepsis. Blood Purif 19:361–368CrossRefPubMed

45.

Nakamura T, Kawagoe Y, Matsuda T, Koide H (2004) Effect of polymyxin B-immobilized fiber on bone resorption in patients with sepsis. Intensive Care Med 30:1838–1841CrossRefPubMed

46.

Nakamura T, Ushiyama C, Suzuki S et al (2000) Effect of polymyxin B-immobilized fiber hemoperfusion on sepsis-induced rhabdomyolysis with acute renal failure. Nephron 86:210CrossRefPubMed

47.

Nakamura T, Ushiyama C, Shoji H, Koide H (2002) Effects of hemoperfusion on serum cardiac troponin T concentrations using polymyxin B-immobilized fibers in septic patients undergoing hemodialysis. ASAIO J 48:41–44CrossRefPubMed

48.

Nakamura T, Ushiyama C, Suzuki Y, Shoji H, Shimada N, Koide H (2002) Hemoperfusion with polymyxin B immobilized fibers for urinary albumin excretion in septic patients with trauma. ASAIO J 48:244–248CrossRefPubMed

49.

Nakamura T, Ushiyama C, Suzuki Y et al (2003) Hemoperfusion with polymyxin B-immobilized fiber in septic patients with methicillin-resistant Staphylococcus aureus-associated glomerulonephritis. Nephron 94:c33–c39PubMed

50.

Coudroy R, Payen D, Launey Y, ABDOMIX Group et al (2017) Modulation by polymyxin-B hemoperfusion of inflammatory response related to severe peritonitis. Shock. 47:93–99CrossRefPubMed

Titel: Polymyxin B-immobilized hemoperfusion and mortality in critically ill adult patients with sepsis/septic shock: a systematic review with meta-analysis and trial sequential analysis
verfasst von: Tomoko Fujii
Riki Ganeko
Yuki Kataoka
Toshi A. Furukawa
Robin Featherstone
Kent Doi
Jean-Louis Vincent
Daniela Pasero
René Robert
Claudio Ronco
Sean M. Bagshaw
Publikationsdatum: 04.12.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Intensive Care Medicine / Ausgabe 2/2018
Print ISSN: 0342-4642
Elektronische ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-017-5004-9

Neu im Fachgebiet AINS

18.04.2024 | Wirbelsäulenmetastase | Nachrichten

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Polymyxin B-immobilized hemoperfusion and mortality in critically ill adult patients with sepsis/septic shock: a systematic review with meta-analysis and trial sequential analysis

Abstract

Purpose

Methods

Results

Conclusions

Registration

Neu im Fachgebiet AINS

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Hochrisiko-Eingriffe für postoperative Übelkeit

Diclofenac-Gel versus Ibuprofen bei akuten Rückenschmerzen

Update AINS

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Registration

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

Focus on paediatrics: 2017

Limited value of end-expiratory inferior vena cava diameter to predict fluid responsiveness impact of intra-abdominal pressure

Status quo of delirium management in German-speaking countries: comparison between intensive care units and wards

Early oseltamivir therapy improves the outcome in critically ill patients with influenza: a propensity analysis

Lack of concordance between ECDC and CDC systems for surveillance of ventilator associated pneumonia

Upper and lower limb muscle atrophy in critically ill patients: an observational ultrasonography study

Neu im Fachgebiet AINS

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Hochrisiko-Eingriffe für postoperative Übelkeit

Diclofenac-Gel versus Ibuprofen bei akuten Rückenschmerzen

Update AINS